Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 12/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901789 | 0.88 | GRM5 (0.51) | KCNH2GRM5S1PR5S1PR1PDCD1 | |
| SCHEMBL4083132 | 0.88 | S1PR5 (0.44) | KCNH2S1PR5S1PR1PDCD1CD274 | |
| SCHEMBL13912802 | 0.88 | S1PR5 (0.43) | KCNH2S1PR5S1PR1PDCD1CD274 | |
| SCHEMBL13901777 | 0.76 | NPC1 (0.51) | S1PR5S1PR1PDCD1CD274S1PR3 | |
| SCHEMBL13901659 | 0.76 | S1PR1 (0.41) | KCNH2S1PR5S1PR1PDCD1CD274 | |
| SCHEMBL13901656 | 0.76 | S1PR5 (0.43) | KCNH2S1PR5S1PR1PDCD1CD274 | |
| SCHEMBL13901782 | 0.76 | S1PR1 (0.46) | S1PR5S1PR1PDCD1CD274S1PR3 | |
| SCHEMBL13901784 | 0.71 | S1PR5 (0.50) | S1PR5S1PR1PDCD1CD274S1PR3 | |
| SCHEMBL13901966 | 0.71 | NPC1 (0.47) | S1PR5S1PR1PDCD1CD274S1PR3 | |
| SCHEMBL13901655 | 0.71 | S1PR5 (0.48) | KCNH2S1PR5S1PR1S1PR3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | KCNH2 4732/4885GRM5 3761/4885S1PR5 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.